These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32631197)

  • 1. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.
    Lynch HF; Bateman-House A
    J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197
    [No Abstract]   [Full Text] [Related]  

  • 2. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
    Speers MA
    Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
    Finkelstein PE
    AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's 'Accelerated Approvals' Are Critical But Raise Thorny Issues.
    Miller HI
    Mo Med; 2019; 116(3):168-169. PubMed ID: 31527930
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 7. Caution urged over the FDA's new breakthrough designation.
    Jiang K
    Nat Med; 2013 Oct; 19(10):1196. PubMed ID: 24100969
    [No Abstract]   [Full Text] [Related]  

  • 8. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
    Galluppi GR; Brar S; Caro L; Chen Y; Frey N; Grimm HP; Rudd DJ; Li CC; Magee M; Mukherjee A; Nagao L; Purohit VS; Roy A; Salem AH; Sinha V; Suleiman AA; Taskar KS; Upreti VV; Weber B; Cook J
    Clin Pharmacol Ther; 2021 Nov; 110(5):1172-1175. PubMed ID: 33991429
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA's post-approval studies continue to suffer delays and setbacks.
    Willyard C
    Nat Med; 2014 Nov; 20(11):1224-5. PubMed ID: 25375913
    [No Abstract]   [Full Text] [Related]  

  • 10. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 12. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 13. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 14. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
    Bateman-House A; Robertson CT
    JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
    [No Abstract]   [Full Text] [Related]  

  • 15. 21
    Paradise J
    Am J Law Med; 2018 May; 44(2-3):309-327. PubMed ID: 30106644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncology Expanded Access and FDA's Project Facilitate.
    Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R
    Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 19. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.